Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
UCLA Jonsson Comp Cancer Center, Los Angeles, California Hoag Memorial Hospital Presbyterian, Newport Beach, California University of Kansas Medical Center, Westwood, Kansas University of Pennsylvania, Philadelphia, Pennsylvania MD Anderson Cancer Center, Houston, Texas Utah Intermountain Medical Center, Murray, Utah China
Novartis Investigative Site, Guangzhou Novartis Investigative Site, Shanghai Novartis Investigative Site, Tianjin France
Novartis Investigative Site, Saint-Cloud, Hauts De Seine Novartis Investigative Site, Bordeaux Novartis Investigative Site, Clermont-Ferrand Novartis Investigative Site, Saint-Herblain Novartis Investigative Site, Strasbourg Germany
Novartis Investigative Site, Cologne Novartis Investigative Site, Erlangen Novartis Investigative Site, Essen Novartis Investigative Site, München Poland
Novartis Investigative Site, Gliwice Portugal
Novartis Investigative Site, Porto Spain
Novartis Investigative Site, L'Hospitalet de Llobregat, Barcelona Novartis Investigative Site, Barcelona, Catalonia Novartis Investigative Site, Barcelona Novartis Investigative Site, Madrid Novartis Investigative Site, Madrid